MLchartDataset catalogue

Elrexfio

Term · Oncology and biomedicine · MLC-T-ONC-002755

A drug used to treat adults with multiple myeloma that came back or did not get better after treatment with at least four other anticancer therapies. These therapies had to include an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Elrexfio binds to a protein called CD3, which is found on T cells (a type of white blood cell), and to a protein called BCMA, which is found on myeloma cells and some types of immune cells. This may help the immune system kill cancer cells. Elrexfio is a type of bispecific T-cell engager. Also called elranatamab.

Table 1. Record
IdentifierMLC-T-ONC-002755
FieldOncology and biomedicine
Synonymselranatamab
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-002755",
  "term": "Elrexfio",
  "field": "Oncology and biomedicine",
  "definition": "A drug used to treat adults with multiple myeloma that came back or did not get better after treatment with at least four other anticancer therapies. These therapies had to include an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Elrexfio binds to a protein called CD3, which is found on T cells (a type of white blood cell), and to a protein called BCMA, which is found on myeloma cells and some types of immune cells. This may help the immune system kill cancer cells. Elrexfio is a type of bispecific T-cell engager. Also called elranatamab.",
  "synonyms": [
    "elranatamab"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/elrexfio/"
}

Record 6,556 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.